Drug Target Review

JANUARY 15, 2024

The preclinical results demonstrated significant immune responses and tumour regression. Could you elaborate on the mechanisms by which these responses are initiated within cancer cells? This induced anti-tumour immunity is also detectable by increased innate and adaptive immune cells in the tumour, spleen and blood.

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. ePoster Abstract # OC48.2

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

The Pharma Data

APRIL 15, 2022

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

JANUARY 19, 2021

With this kind of a start, 2021 may be scorching. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. TCR2 Therapeutics – The Cambridge, Mass.

Small Molecule 52

Small Molecule Laboratories Immune Response Trials 52

Drug Discovery World

MAY 6, 2024

billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. During the period 2016-2021, the Brazilian, Chinese and Indian markets grew by 11.7%, 6.7% However, Europe is facing increasing competition from emerging economies.

Drugs 147

Drugs Molecular Biology Science Clinical Trials 147

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors.

Therapies 52

Therapies Immune Response Research Engineering 52

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. His mentorship produced numerous publications.

Engineering 104

Engineering Virus Therapies Immune Response 104

The Pharma Data

JANUARY 31, 2021

1, 2021 12:05 UTC. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

JANUARY 17, 2021

18, 2021 09:00 UTC. LONDON–( BUSINESS WIRE )– Ixaka Ltd , an integrated cell and gene therapy company focused on the natural power of the body to cure disease, launches today. Our focus is now on accelerating progress to help realise the potential for durable and curative cell and gene therapies. A total of $15.4

Therapies 40

Therapies Clinical Trials Immune Response Disease 40

Drug Discovery World

JULY 22, 2022

Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours.

Therapies 130

Therapies Treatment Engineering Clinical Trials 130

The Pharma Data

MAY 12, 2021

New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders. Additional data to be shared on rilzabrutinib, an investigational, peripheral Bruton’s tyrosine kinase (BTK) inhibitor with Tailored Covalency ® technology intended to treat immune thrombocytopenic purpura (ITP).

Disease 40

Disease FDA Treatment Therapies 40

Drug Discovery World

APRIL 20, 2023

Biological mechanisms Given its prevalence and potential economic, societal and patient burden, post-Covid cognitive impairment seems an important target for treatment, be that through existing rehabilitations services, or digital, drug or biologic therapies. 2021, doi: 10.1038/ s41598-021-92045-x. 2021, doi: 10.1016/j.eclinm.2021.101019.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

APRIL 8, 2021

AstraZeneca will share updates from the Company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. Key AstraZeneca presentations during AACR 2021. AstraZeneca in oncology.

DNA 52

DNA Immune Response Therapies Treatment 52

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

JANUARY 11, 2021

11, 2021 23:59 UTC. a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. 21, 2021, online.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

The Israeli-based biotech is dedicated to developing innovative therapies for cancer, based on its proprietary research of newly discovered immune-checkpoints and immune-evasion mechanisms. Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 3, 2021

Both Jerry and Jeff have proven and successful track records in the design and execution of early and late-stage clinical trials that have evaluated novel immune therapies. The backbone of NexImmune’s approach is its proprietary Artificial Immune Modulation (AIM TM ) nanoparticle technology platform. GAITHERSBURG, Md.,

Immune Response 40

Immune Response Clinical Trials Therapies Cell Biology 40

The Pharma Data

MAY 15, 2023

The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases,” said Flavius Martin, M.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 21, 2021

The 2021 trend of biotech initial public offerings (IPOs) continued this week. Precigen is focused on next-generation gene and cell therapy using precision technology. On January 5, 2021, the U.S. Here’s a look. Precigen – Germantown, Md.-based based Precigen announced its pricing of its $112.5 million IPO at a price of $7.50

Immune Response 52

Immune Response Laboratories Trials FDA 52

The Pharma Data

NOVEMBER 9, 2020

Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and they are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. NBTXR3 is injected one time, directly into solid tumors. Abstract ID: 410.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

JANUARY 17, 2021

The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. We will continue to collaborate with the FDA during their review process and in parallel build our commercial readiness for a potential approval and commercial launch in the first quarter of 2021.”.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. CHENGDU, China , Feb. These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.”

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

OCTOBER 21, 2020

(Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20 for treatment of non-Hodgkin’s lymphoma (NHL). T cell therapy in NHL patients.

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

DECEMBER 30, 2020

This week, Bloomberg reported companies agreed to slash the prices of 119 new therapies that treat a range of illnesses, including pulmonary disease, lupus, diabetes and cancer. Top line data are expected in late January or early February 2021. No drug-related serious adverse events have been reported as of today.

Immune Response 52

Immune Response Vaccine Clinical Trials Production 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — ImaginAb Inc. , Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer?BioNTech Procedures should be in place to avoid injury from fainting. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ About the PEGASUS study.

Immune Response 52

Immune Response Trials Treatment Disease 52

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 138

Therapies DNA Virus Clinical Trials 138

The Pharma Data

DECEMBER 27, 2020

NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021. .–( BUSINESS WIRE )– Lineage Cell Therapeutics, Inc.

Therapies 52

Therapies Clinical Trials Production Treatment 52

The Pharma Data

JANUARY 17, 2021

18, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences (Formerly Known As Taconic Farms, Inc.) Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. RENSSELAER, N.Y.,

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

The Pharma Data

DECEMBER 20, 2020

USA (known as MSD outside the United States and Canada), the first set of evaluable patients (n = 8) diagnosed with 2 nd or 3 rd line WT1(+) relapsed or refractory metastatic ovarian cancer demonstrated a disease control rate (the sum of overall response rate and rate of stable disease) of 87.5% Kenilworth, N.J., with a median follow-up of 9.4

Immune Response 52

Immune Response Clinical Trials Therapies Trials 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 104

Therapies Engineering Molecular Biology Immune Response 104

The Pharma Data

OCTOBER 26, 2020

Testing Therapies, Antivirals and Vaccines. based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus. They expect to launch a Phase III trial of the drug in the first quarter of 2021. . Other Industry News. Please read more here. .

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52